Is Cidara Therapeutics Inc (CDTX) overvalued? · rev $1.3M
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
This page asks whether Cidara Therapeutics Inc (CDTX) looks expensive on cached numbers — not a short thesis.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
CDTX currently screens at market cap $6.96B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CDTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CDTX stock page for the full model, not this heading.
Not investment advice.